SEQUENCE LISTING

<110> DUFT, BRADFORD J.
      KOLTERMAN, ORVILLE G.

<120> METHODS FOR TREATING OBESITY

<130> 18528.230

<140> 09/445,517
<141> 1999-12-06

<150> 08/870,762
<151> 1997-06-06

<160> 20

<170> PatentIn Ver. 3.3

<210> 1
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 1
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
  1   5   10   15

Val His Ser Ser Asn Asn Phe Gly Pro Val Leu Pro Pro Thr Asn Val
             20   25   30

Gly Ser Asn Thr Tyr
          35

<210> 2
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<220>
<223> 2,7-Cyclo bridge

<400> 2
Lys Asp Asn Thr Ala Thr Lys Ala Thr Gln Arg Leu Ala Asn Phe Leu
  1   5   10   15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Pro Ser Thr Asn Val
             20   25   30

1

Gly Ser Asn Thr Tyr
        35

<210> 3
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 3
Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
 1   5   10   15

His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val Gly
            20   25   30

Ser Asn Thr Tyr
        35

<210> 4
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 4
Ala Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1   5   10   15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
            20   25   30

Gly Ser Asn Thr Tyr
        35

<210> 5
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 5
Ser Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1   5   10   15

2

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
            20   25   30

Gly Ser Asn Thr Tyr
        35

<210> 6
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 6
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
   1   5   10   15

Val His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val
            20   25   30

Gly Ser Asn Thr Tyr
        35

<210> 7
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 7
Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
   1   5   10   15

His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val Gly
            20   25   30

Ser Asn Thr Tyr
        35

<210> 8
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 8
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
  1   5   10   15

Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val
              20   25   30

Gly Ser Asn Thr Tyr
          35

<210> 9
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 9
Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
  1   5   10   15

Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val Gly
              20   25   30

Ser Asn Thr Tyr
          35

<210> 10
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 10
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
  1   5   10   15

Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
              20   25   30

Gly Ser Asn Thr Tyr
          35

<210> 11
<211> 36
<212> PRT
<213> Artificial Sequence

<220>

4

<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 11
Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
  1   5   10   15

Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly
              20   25   30

Ser Asn Thr Tyr
          35

<210> 12
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 12
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
  1   5   10   15

Val His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
              20   25   30

Gly Ser Asn Thr Tyr
          35

<210> 13
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 13
Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
  1   5   10   15

His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly
              20   25   30

Ser Asn Thr Tyr
          35

<210> 14
<211> 37
<212> PRT

5

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<220>
<221> MOD_RES
<222> (1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MOD_RES
<222> (2)
<223> Variable amino acid

<220>
<221> MOD_RES
<222> (7)
<223> Variable amino acid

<220>
<221> MOD_RES
<222> (13)
<223> Ala, Ser, or Thr

<220>
<221> MOD_RES
<222> (17)
<223> Val, Leu, or Ile

<220>
<221> MOD_RES
<222> (18)
<223> His or Arg

<220>
<221> MOD_RES
<222> (19)
<223> Ser or Thr

<220>
<221> MOD_RES
<222> (20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MOD_RES
<222> (21)
<223> Asn, Gln, or His

<220>
<221> MOD_RES
<222> (23)
<223> Phe, Leu, or Tyr

<220>

```
<221> MOD_RES
<222> (26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MOD_RES
<222> (29)
<223> Ser, Pro, or Thr

<220>
<221> MOD_RES
<222> (31)
<223> Asn, Asp, or Gln

<220>
<223> c-term may be amino, alkylamino, dialkylamino,
      cycloalkylamino, arylamino, aralkylamino, alkyloxy,
      aryloxy, or aralkyloxy

<220>
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 14
Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
 1               5                  10                  15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Pro Xaa Thr Xaa Val
            20                  25                  30

Gly Ser Asn Thr Tyr
          35


<210> 15
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<220>
<221> MOD_RES
<222> (1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MOD_RES
<222> (2)
<223> Variable amino acid

<220>
<221> MOD_RES
<222> (7)
<223> Variable amino acid
```

7

```
<220>
<221> MOD_RES
<222> (13)
<223> Ala, Ser, or Thr

<220>
<221> MOD_RES
<222> (17)
<223> Val, Leu, or Ile

<220>
<221> MOD_RES
<222> (18)
<223> His or Arg

<220>
<221> MOD_RES
<222> (19)
<223> Ser or Thr

<220>
<221> MOD_RES
<222> (20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MOD_RES
<222> (21)
<223> Asn, Gln, or His

<220>
<221> MOD_RES
<222> (23)
<223> Phe, Leu, or Tyr

<220>
<221> MOD_RES
<222> (26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MOD_RES
<222> (28)
<223> Ser, Pro, Leu, Ile, or Thr

<220>
<221> MOD_RES
<222> (31)
<223> Asn, Asp, or Gln

<220>
<223> c-term may be amino, alkylamino, dialkylamino,
      cycloalkylamino, arylamino, aralkylamino, alkyloxy,
      aryloxy, or aralkyloxy

<220>
```

8

<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 15
Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
  1   5   10   15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Xaa Pro Thr Xaa Val
           20   25   30

Gly Ser Asn Thr Tyr
         35

<210> 16
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<220>
<221> MOD_RES
<222> (1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MOD_RES
<222> (2)
<223> Variable amino acid

<220>
<221> MOD_RES
<222> (7)
<223> Variable amino acid

<220>
<221> MOD_RES
<222> (13)
<223> Ala, Ser, or Thr

<220>
<221> MOD_RES
<222> (17)
<223> Val, Leu, or Ile

<220>
<221> MOD_RES
<222> (18)
<223> His or Arg

<220>
<221> MOD_RES
<222> (19)
<223> Ser or Thr

```
<220>
<221> MOD_RES
<222> (20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MOD_RES
<222> (21)
<223> Asn, Gln, or His

<220>
<221> MOD_RES
<222> (23)
<223> Phe, Leu, or Tyr

<220>
<221> MOD_RES
<222> (25)
<223> Ala, or Pro

<220>
<221> MOD_RES
<222> (26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MOD_RES
<222> (31)
<223> Asn, Asp, or Gln

<220>
<223> c-term may be amino, alkylamino, dialkylamino,
      cycloalkylamino, arylamino, aralkylamino, alkyloxy,
      aryloxy, or aralkyloxy

<220>
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 16
Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
 1               5                  10                  15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Xaa Xaa Leu Pro Pro Thr Xaa Val
            20                  25                  30

Gly Ser Asn Thr Tyr
        35


<210> 17
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
```

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<220>
<221> MOD_RES
<222> (1)
<223> Lys, Ala, Ser, or not present

<220>
<221> MOD_RES
<222> (2)
<223> Variable amino acid

<220>
<221> MOD_RES
<222> (7)
<223> Variable amino acid

<220>
<221> MOD_RES
<222> (13)
<223> Ala, Ser, or Thr

<220>
<221> MOD_RES
<222> (17)
<223> Val, Leu, or Ile

<220>
<221> MOD_RES
<222> (18)
<223> His or Arg

<220>
<221> MOD_RES
<222> (19)
<223> Ser or Thr

<220>
<221> MOD_RES
<222> (20)
<223> Ser, Thr, Gln, or Asn

<220>
<221> MOD_RES
<222> (21)
<223> Asn, Gln, or His

<220>
<221> MOD_RES
<222> (23)
<223> Phe, Leu, or Tyr

<220>
<221> MOD_RES
<222> (26)
<223> Ile, Val, Ala, or Leu

<220>
<221> MOD_RES
<222> (31)
<223> Asn, Asp, or Gln

<220>
<223> c-term may be amino, alkylamino, dialkylamino,
      cycloalkylamino, arylamino, aralkylamino, alkyloxy,
      aryloxy, or aralkyloxy

<220>
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 17
Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu
  1   5   10   15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Pro Pro Thr Xaa Val
            20   25   30

Gly Ser Asn Thr Tyr
          35

<210> 18
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide construct

<400> 18
Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val
  1   5   10   15

Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe
            20   25   30

<210> 19
<211> 37
<212> PRT
<213> Rattus norvegicus

<400> 19
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
  1   5   10   15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
            20   25   30

Gly Ser Asn Thr Tyr
          35

```
<210> 20
<211> 37
<212> PRT
<213> Homo sapiens

<400> 20
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1               5                  10                  15


Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
            20                  25                  30


Gly Ser Asn Thr Tyr
        35
```